Experimental cell therapy for advanced cancers shows early promise but study halted
NCT ID NCT06077903
First seen May 08, 2026 · Last updated May 20, 2026 · Updated 4 times
Summary
This early-phase trial tested a personalized cell therapy called GT101 for people with advanced solid tumors that had spread or come back. The treatment involved collecting immune cells from the patient's own tumor, growing them in a lab, and infusing them back along with chemotherapy and interleukin-2. The main goal was to check safety, but the study was stopped early after enrolling only 10 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.